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Abstract
Background: The objective of this study was to describe randomized controlled trials (RCTs) and controlled clinical trials
(CCTs) in child health published between 1948 and 2006, in terms of quantity, methodological quality, and publication and
trial characteristics. We used the Trials Register of the Cochrane Child Health Field for overall trends and a sample from this
to explore trial characteristics in more detail.
Methodology/Principal Findings: We extracted descriptive data on a random sample of 578 trials. Ninety-six percent of the
trials were published in English; the percentage of child-only trials was 90.5%. The most frequent diagnostic categories were
infectious diseases (13.2%), behavioural and psychiatric disorders (11.6%), neonatal critical care (11.4%), respiratory
disorders (8.9%), non-critical neonatology (7.9%), and anaesthesia (6.5%). There were significantly fewer child-only studies
(i.e., more mixed child and adult studies) over time (P=0.0460). The proportion of RCTs to CCTs increased significantly over
time (P,0.0001), as did the proportion of multicentre trials (P=0.002). Significant increases over time were found in
methodological quality (Jadad score) (P,0.0001), the proportion of double-blind studies (P,0.0001), and studies with
adequate allocation concealment (P,0.0001). Additionally, we found an improvement in reporting over time: adequate
description of withdrawals and losses to follow-up (P,0.0001), sample size calculations (P,0.0001), and intention-to-treat
analysis (P,0.0001). However, many trials still do not describe their level of blinding, and allocation concealment was
inadequately reported in the majority of studies across the entire time period. The proportion of studies with industry
funding decreased slightly over time (P=0.003), and these studies were more likely to report positive conclusions
(P=0.028).
Conclusions/Significance: The quantity and quality of pediatric controlled trials has increased over time; however, much
work remains to be done, particularly in improving methodological issues around conduct and reporting of trials.
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Introduction
Controlled trials have led to some notable advances in pediatric
medicine. Famously, the trials of polio vaccines in many countries
during the 1950s paved the way for the near-eradication of this
disease [1,2]. During the 1950s and 1960s, neonatologist William
Silverman used the randomised controlled trial study design to test
several commonly-used treatments, often demonstrating their lack
of effectiveness[3–6]. More recently, clinical trials in childhood
cancer have resulted in steady improvement in survival rates [7].
Overall, however, it has long been recognized in the pediatric
research community that there is a paucity of child-relevant
evidence available from controlled trials[8].
The reasons for the lack of controlled trials in child health are
numerous, including among others: parental reluctance to agree to
the participation of their children in research studies involving
unproven treatments; the difficulty of recruiting adequate sample
sizes, particularly for uncommon conditions; ethical concerns; and
perceptions among drug manufacturers that testing drugs in
children brings the risk of increased liability [9], [10].
The fact that many interventions carried out on children are
inadequately tested has direct implications for child health. For
example, the lack of evidence about the efficacy and effectiveness
of many drugs means that selection and dosage of drugs
administered to children is often done at the discretion of
individual physicians, with choices based on extrapolation from
studies in adults, a practice known as ‘‘off-label prescribing’’ [11].
Due to children’s differing developmental and physiological
processes, such extrapolation is often not appropriate. Adult-
extrapolated dosing in children may either lead to overdosing (with
the possibility of toxic effects) or under dosing (ineffective therapy)
[11]. Moreover, outcomes in children, particularly young children,
can be different than those in adults tested with the same
intervention (see for example[12]); also, the goals of treatment for
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ensure decades of life, with as high a quality of life as possible,
whereas adults usually have to live with the effects of treatment for
a much shorter time [13].
In recent years, there have been developments in both the U.S.
and Europe that appear likely to increase the number of controlled
trials in pediatrics. Legislation, such as the US Best Pharmaceu-
ticals for Children Act (2002, renewed 2007) and Pediatric
Research Equity Act (2003) and the European Pediatric Rule
(2007), has been introduced encouraging drug manufacturers to
evaluate the safety and effectiveness of products in pediatric
patients, if the intervention is likely to be used in a substantial
number of children, or provide a more meaningful therapeutic
benefit to pediatric patients than existing treatments [10,14–16].
For example, in the US, amendments in 1997 to Federal Food,
Drug, and Cosmetic Act, along with the 2002 Best Pharmaceu-
ticals for Children Act (BPCA), provided economic incentives to
pharmaceutical companies to encourage them to perform research
on the safety, efficacy, dosing and unique risks associated with
medications for children [10][17]. This legislation, of course,
specifically addresses testing of pharmaceuticals. There is currently
no equivalent requirement for testing of non-drug interventions,
such as behavioural or social programmes; trials of these
interventions make up a substantial proportion of child health
trials, as will be discussed later in this paper.
Given the need for child-specific evidence for the appropriate
delivery of health care interventions, a survey of the state of
existing research is valuable, both as a benchmark and as a guide
for future improvement. We used the Cochrane Child Health
Field’s Trials Register, a database of over 30,000 randomized
controlled trials (RCTs) and controlled clinical trials (CCTs) in
child health, to carry out this survey [18]. We defined RCTs and
CCTs following the guidance in the Cochrane Handbook for
Systematic Reviews of Interventions, whereby randomized
controlled trials are conducted on groups established by random
allocation which is explicitly described by the authors; the term
‘‘controlled clinical trial’’ is applied to studies for which it is not
possible to determine if randomization was used, or if quasi-
random methods of assignment were used [19]. The objective of
our study was to describe child health RCTs and CCTs, published
between 1948 and 2006, in terms of quantity, methodological
quality, and publication and trial characteristics.
Results
Our description of pediatric trials is based on analysis of the
Child Health Field Trials Register as a whole, along with in-depth
analysis of a random sample of trials from each time period.
Characteristics of the entire Child Health Field Trials
Register
The number of trials per year in the Child Health Field Trials
Register ranged from a low of 3 (1948) to a high of 2,722 (2004).
The number of RCTs and CCTs published each year has, overall,
steadily increased (Figure 1).
We analysed pediatric trials as a proportion of total trials in the
Cochrane Central Register of Controlled Trials (CENTRAL), a
bibliographic database of controlled trials that have been identified
through handsearching and database searching (Figure 2). This
analysis was done in order to estimate the proportion of total
published trials that are concerned with child health. We did this
comparison for the years 1948 to 2005, since our Trials Register
was not complete for 2006 at the time of this study. The number of
trials in the Child Health Field Trials Register represents a
proportion of all trials in CENTRAL ranging between 1.66%
(1948) and 10.7% (2004) (Figure 2).
Figure 1. Number of RCTs and CCTs in the Child Health Field Trials Register, 1948–2005. NB. The numbers are only graphed to 2005
because this is the last complete year in the Trials Register. The dip in trials in 2001 is unexplained.
doi:10.1371/journal.pone.0013106.g001
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our sample of 578 trials
Table 1 presents the characteristics of a sample of 578 studies
from the Child Health Field Trials Register. This sample was
taken from the Trials Register according to a protocol outlined in
our Materials and Methods section, and data extraction was
carried out to identify publication and trial characteristics for each
study, along with assessment according to the Jadad scale[20].
Almost all (96.0%) of the trials were published in English. The
corresponding authors for almost half (49.0%) of the trials were
based in either the United States or the United Kingdom. The
overall percentage of child-only trials was 90.5% (95% CI: 86.4,
94.5%). 396 (68.5%) trials investigated drug products and 173
(29.9%) were placebo-controlled
The most frequent diagnostic categories of the included trials were:
infectious diseases (13.2%), behavioural and psychiatric disorders
(11.6%), neonatal critical care (11.4%), respiratory disorders (8.9%),
non-critical neonatology (7.9%), and anaesthesia (6.5%).
1. Trends over time. There was a trend towards fewer child-
only studies (i.e. more mixed child and adult studies) over time (P-
value: 0.046); this value is statistically significant at the 5% level,
but not under any correction for multiple testing.
The proportion of RCTs to CCTs increased significantly over
time (Figure 3a) (P,0.0001). The majority of RCTs were of a
parallel design (Figure 3b).
The proportion of multi-centre trials increased over time
(P=0.002). There was no significant change in the proportion of
multinational studies over time, however the sample size of
multinational trials in our sample was small (n=17) (P=0.15).
While the number of trials did increase over time, the median
sample size of studies followed a parabolic trend—the numbers
went steadily down until the late 1980s and have started to come
up again since then (Table 2).
2. Methodological Quality. Methodological quality as
assessed by the Jadad score increased significantly over time
(P,0.0001); we also reanalyzed the data minus the first period
(1948–1953) (where the average Jadad score was much lower) and
the increase over time was still highly significant (p=0.0002)
(Figure 4).
The proportion of double-blind studies increased over time
(P,0.0001). To assess if the level of blinding changed over time,
we ordered the 5 possible responses from least blinding to most
blinding (unblind, not described, single, double, triple-blind) and
found a significant increase (P=0.007). As shown in Figure 5,
many trials still do not describe their level of blinding; even in the
Figure 2. Trials in the Child Health Field Trials Register against trials in CENTRAL, 1948-2005. NB: In both the Trials Register and
CENTRAL, there is a dip in numbers in 2001. This is unexplained.
doi:10.1371/journal.pone.0013106.g002
Table 1. Characteristics of trials sampled from the Child
Health Trials Register (n=578).
Variable Category Estimate % (95% CI)
Design CCT 10.9 (7.8, 13.9)
RCT 89.1 (86.1, 92.2)
Intervention Pharmaceutical 67.2 (61.2, 73.2)
Non-Pharmaceutical 32.8 (26.8, 38.8)
Journal Pediatric 32.8 (26.6, 39.0)
Medical 61.5 (55.1, 67.9)
Other 5.7 (2.4, 8.9)
Country of
corresponding author
USA 38.3% (32.0%, 44.6%)
UK 10.7% (6.6%, 14.9%)
Jadad Score Median (IQR) 2 (1, 3)
doi:10.1371/journal.pone.0013106.t001
Controlled Trials in Children
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e13106most recent time period, 2002–2006, 37.7% of authors did not
include this description.
To estimate the progression of allocation concealment over
time, we ordered the three possibilities as inadequate,
unclear, adequate, and found that there was an increase in
adequate allocation concealment over time (P,0.0001).
However, allocation concealment was inadequately reported
in the majority of studies across the entire time period
(Figure 6).
Additionally, our regression analysis found an increase in
reporting of the following characteristics over time: adequate
description of withdrawals and losses to follow-up (p-value,
0.0001);samplesizecalculations(P-value,0.0001);andintention-to-
treat analysis (P,0.0001).
Figure 3. Characteristics of the study design in our sample. a. Relative proportions of RCTs and CCTs over time from 1948 to 2006. b. Designs
of RCTs over time from 1948–2006.
doi:10.1371/journal.pone.0013106.g003
Table 2. Sample sizes over time.
1948–1953 1954–1959 1960–1965 1966–1971 1972–1977 1978–1983 1984–1989 1990–1995 1996–2001 2002–2006
Mean 257 714 354 793 592 195 225 182 136 281
Median 101 100 96 70 54 50 40 50 60 99
doi:10.1371/journal.pone.0013106.t002
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conclusions. For each study, we recorded if the authors
declared a source of funding for the study and whether the
funding came from industry (pharmaceutical or other corporations).
The non-pharmaceutical companies in our sample all had interests
related to the topic of the study. For example, M & R Laboratories
and its successor company Ross Laboratories, manufacturer of
infant formula, supported several studies involving infant formula.
The IVAC Corporation, a manufacturer of infant incubators,
supplied equipment for one study. IBM provided five programmed
instruction machines for children with learning disabilities for a
study testing the effectiveness of these machines.
We analysed the relationship between declared funding from
industry and whether the overall conclusions of the article were
positive or negative (Table 3). In order to decide whether the
overall study conclusion was positive, negative, or unclear,
reviewers considered the objective or aim of that study. If the
authors of the study stated that they had achieved their objective
Figure 4. Mean Jadad score over time.
doi:10.1371/journal.pone.0013106.g004
Figure 5. Level of blinding over time from 1948-2006.
doi:10.1371/journal.pone.0013106.g005
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authors stated they did not achieve the objective or aim, overall
conclusions were reported as negative. A decision of ‘‘unclear’’ was
made if the authors did not clearly state their objective or aim, or if
the conclusions to their study were inconclusive. The probability of
reporting positive conclusions was significantly higher for studies
with industry funding (p=0.028) (Table 4). There is evidence that
the proportion of studies with industry funding decreased slightly
over time (P=0.003).
Discussion
The size, span and comprehensiveness of our register have
allowed us to describe the state of pediatric research over a period
of almost sixty years. This is the first comprehensive mapping of
research in pediatrics in this way. The results highlight gaps and
inadequacies in the research conducted to date and provide a
baseline to examine future developments in pediatric research.
Our map of this research shows several encouraging trends,
although all of these developments come with some caveats. For
example, we found that the number of clinical trials published
each year has steadily increased. This is possibly a positive
development assuming that increasing number of trials have led to
greater amount of knowledge about the effects of treatment. This
result is offset by the fact that it is clear that, as shown in Figure 1,
the rate of publication of controlled trials in pediatrics has not
increased at the same rate as for trials as a whole. It is also
encouraging that the methodological quality, as indicated by Jadad
scores along with several other quality indicators, increased over
time. Further, the proportion of trials that were randomized also
increased; this proportion was calculated with the denominator
being all studies, while the numerator was the number described as
randomized.
However, our results demonstrate that it is starkly evident that
there is room for considerable future progress. The median Jadad
score did not exceed 2 out of a maximum of 5 points in any
particular time period. Allocation concealment, although generally
improving over time, was still classed as inadequate or unclear in
83% of trials in our most recent time period, and in no time period
was it classed as adequate in more than 26.5% of cases (1996–2001).
This highlights the issue of inadequate reporting, as does the fact
that in over the time periods 25.6% to 62.8% of authors did not
report on their blinding techniques. Of course, a limitation of any
quality assessment endeavour is that study authors do not
necessarily report on all methodological aspects of their trial. Trial
authors might not report on certain methodological aspects, even
though these may have been done to a high standard in the trial.
This fact might be especially important in investigating historical
trends, where increasing recognition over time of the need to report
features such as allocation concealment might lead to apparent
improvements in trial quality, simply because journal editors are
requiring that authors be more descriptive about their methods.
Figure 6. Allocation concealment over time (RCTs only).
doi:10.1371/journal.pone.0013106.g006
Table 3. Authors’ conclusions by funding source.
Industry Funding Conclusions Estimate (95% CI)
Yes Positive 86.0% (76.0%, 96.1%)
Negative 9.6% (0.4%, 18.8%)
Unclear 4.4% (0.0%, 8.9%)
No Positive 69.1% (58.0%, 80.3%)
Negative 21.6% (11.5%, 31.7%)
Unclear 9.3% (2.3%, 16.2%)
p-value comparing probability of positive conclusion: 0.028.
p-value comparing probability of negative conclusion: 0.085.
doi:10.1371/journal.pone.0013106.t003
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adults are much more likely than those involving children to be
RCTs or systematic reviews, and that studies of therapies
constitute a lower percentage of overall published trials in children
than in adults[20]. Our work amplifies this concern by showing
that, even when a high-quality study design is used in pediatric
research, the conduct and reporting of the trial is often inadequate.
Driven by concern about the potential impact of this poor
reporting on the quality and applicability of child health trials, a
group of pediatric clinicians, methodologists and policy makers,
including some of the authors of this article, have formed the StaR
Child Health initiative, which is aimed at promoting the use of
evidence-based standards or guidance for clinical studies with
children [21]. These standards will be developed in several
domains, building on recent work by StaR Child Health members
in areas such as core outcome measures and risk of bias
assessment[22,23].
Our results are congruent with studies of methodological quality
in other disciplines. A recent systematic review examining 35
studies of methodological quality and trends in various medical
disciplines [24] found that progress over time in these disciplines in
key variables such as allocation concealment, blinding and
randomization was variable. For example, they report that,
among the studies included in their review, the proportions of
RCT authors reporting an adequate method of allocation
concealment did not ever exceed 50%, and in several studies,
were less than 20%.
The increase in the number of multi-centre and multinational
trials is also encouraging. This trend may be a response to the
difficulty of designing adequately-powered trials of interventions
used to treat pediatric conditions which are frequently compar-
atively rare.
We noted several points which warrant further research. For
example, we are unable to ascertain the cause of the dramatic
jump in the number of trials, noted in 2002 and subsequently. One
possible explanation is the impact of previously mentioned
legislation in the US and subsequently the EU that brought in
more tangible incentives and repercussions for drug manufacturers
with regard to testing their products on children. The goal of this
legislation was to encourage pediatric study; however, it has been
shown that pediatric exclusivity provisions can generate lucrative
returns on investment [25], [26], [27]. It would also be interesting
to see if this legislation is related at all to the trend we noted of a
decrease in child-only studies over time, as manufacturers may
have moved to including children in larger studies in order to
prolong market exclusivity of drugs with both pediatric and adult
indications but proportionately a much larger adult market share.
It would also be interesting to analyse changes in the number of
trials currently being conducted and/or registered, to compare
these figures with the number of trials published. Recent work
analysing the rate of registration of pediatric trials suggests that
authors of pediatric trials have been slow to prospectively register
their studies, despite the fact that many journals stipulate that
prospective registration is a prerequisite for publication[28,29].
Therefore it seems likely that analysing the number of registered
trials would substantially underestimate the number of trials
actually being conducted.
Our findings that trials supported by industry funding tend to
have positive conclusions more often than those reporting other
sources of funding are similar to what has been demonstrated in
many other medical disciplines. In a qualitative systematic review
of 19 studies examining the relationship of pharmaceutical
industry funding and clinical trial results, Sismondo [30]
demonstrated a broad range of situations in which industry
funding has effects on trial results, including over-publication of
positive results and under-publication of negative ones, design
biases, duplication of known positive results, and influences on the
interpretation of data. He argues that no further research is
needed in this area, since the existing work is so conclusive.
To date, little work has been done to examine this relationship
in pediatric research. Nkansah et al [31] conducted a small study
examining the relationship between industry sponsorship and
study outcomes in randomized trials assessing calcium supple-
mentation in healthy children. They did not find a significant
association; however, the studies in their sample showed minimal
variability in study results or sponsorship (16/19 studies were
industry funded to some degree, and 17/19 reported statistically
significant improvement of bone density with calcium supplemen-
tation), which limited the authors’ ability to detect associations.
Also, as our sample indicated that the proportion of trials reporting
industry funding had decreased slightly over time, it would be
interesting to examine this trend in more detail.
Study limitations
The sampling procedure used for our trials was a necessity,
given the size of the database we were working with. However, it
did create a lack of precision in certain aspects of our analysis. For
example, although we were able to find trends over time in quality
indicators, we could not identify certain key years or time periods
in which the quality increased more than others. This meant that
we could not, for example, establish whether the 1996 publication
of CONSORT led to increases in the quality of pediatric
trials{Kane, 2007 400071/id;Moher, 2001 400072/id;Plint,
2006 400073/id}. Future research to examine the impact of
CONSORT on pediatric trials would be of value. At the time of
the random sampling we had not yet translated 21 non-English
studies that were later eligible for inclusion. We were able to
describe trends in pediatric trials as a whole; however, further
work in specific areas of pediatric health would illuminate
strengths and weaknesses of study design and reporting in different
disciplines.
Another source of limitations comes from our reliance on
CENTRAL as a source for our Trials Register and hence for the
sample for this study. The fact that we did not carry out a search
for grey literature introduces the possibility of publication bias. As
well, CENTRAL is not a comprehensive source of all published
Table 4. Industry funding over time.
1948–1953 1954–1959 1960–1965 1966–1971 1972–1977 1978–1983 1984–1989 1990–1995 1996–2001 2002–2006
Yes 18.20% 25.00% 13.20% 25.00% 13.50% 9.30% 10.00% 5.20% 17.50% 12.30%
No 11.40% 15.60% 31.90% 29.50% 33.80% 25.00% 24.20% 29.80% 27.90% 39.70%
Unclear 70.50% 59.40% 54.90% 45.40% 52.70% 65.70% 65.80% 65.10% 54.60% 48.00%
doi:10.1371/journal.pone.0013106.t004
Controlled Trials in Children
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e13106trials. For example, Arabic, Chinese and other character-based
languages are not supported by the current software. It is also
possible that the way CENTRAL has been created has led to
artefacts in relation to apparent trends in its content; for example,
handsearching activity by Cochrane Review Groups may favour
more recent trials.
It was also not possible with this study design to directly
determine the impact of increasing numbers of trials on child
health outcomes.
Materials and Methods
The Cochrane Collaboration exists to improve health care by
producing and disseminating systematic reviews of evidence about
health care interventions. Within the Collaboration, groups known
as ‘‘Fields’’ facilitate the production and dissemination of reviews
related to their specialist area of health care. The Cochrane Child
Health Field (the Field) carries out these responsibilities for the
child health community.
The Field maintains a reference-based Trials Register that
contains approximately 30,000 bibliographic records of child
health randomised controlled trials (RCTs) and controlled clinical
trials (CCTs), published from 1948 onwards. Records within the
Trials Register originate from the Cochrane Central Register of
Controlled Trials (CENTRAL). CENTRAL is comprised of
records of studies from Medline, Embase, handsearch results,
grey literature and trials registers of 52 Cochrane Review Groups
that are published internationally in many languages[32].
CENTRAL has also been demonstrated to be the single best
source of controlled trials for Cochrane reviews[33]. To build the
Child Health Field Trials Register, we searched CENTRAL in
July 2002; an update was conducted in March 2006. A sensitive
pediatric search filter was used for these searches, which is
reproduced in Table S2. Included studies were identified by
scanning the title and abstract of each record. If the reviewer could
not determine eligibility from the title and abstract, the full text of
the study was retrieved.
The inclusion criteria for the Trial Register are as follows:
# Study design must be an RCT or CCT, as defined by the
Cochrane Collaboration.[19]
# All pregnancy studies are excluded. The lower age limit
of the register will be the moment after birth.
# Studies on breastfeeding are included because breastfeed-
ing is a form of infant nutrition.
# If the lower age limit is between 13 and 18 and the upper
age limit is 22+ years, the study is excluded.
# If the lower age limit is between 13 and 17 years and the
upper age limit is 21 years or less, the study is
included[18].
This register is a unique resource for the systematic evaluation of
the development of randomized controlled trials and controlled
clinical trials across the discipline of pediatrics. These two types of
study designs are considered to yield the most reliable information
on the efficacy and effectiveness of healthcare interventions.
Comparison of pediatric trials to total number of trials
In March, 2008, we searched the Cochrane Central Register of
Controlled Trials (CENTRAL), for the number of trials for each
year between 1948 and 2005. This was done year by year by
restricting the date range to an individual year. The results were
then compared to the number of trials in the Field Trials Register,
to establish the percentage of trials for each year that were in the
area of child health. We did not include 2006 in this analysis
because the search update for the Trials Register was conducted in
March 2006 and therefore our numerator would have been
inaccurate.
Sample identification
Initially, we started with a sample of 588 trials, published
between 1948 and 2006. All studies in the Trials Register that
were published prior to 1960 were automatically included because
of the small number of studies in these years (n=118). Trials from
all the years from 1960 to 2006 were sampled (using simple
random sampling) at 10 trials per year. During data extraction
studies that were found not be RCTs or CCTs - or that did not
meet the age range criteria of the Trials Register - were excluded
from our sample and were also removed from the Trials Register.
We replaced the excluded studies by randomly selecting another
study when there were other studies published during the same
years. However, for the years 1948 to 1959, there were no other
trials to draw from, so when trials from these years were excluded
they could not be replaced; therefore, the final number of trials
from this time period was 108. Hence we had a final total of 578
trials available for analysis. We did not limit inclusion of trials in
our sample by language of publication. Table S1 presents the
percentage of trials from each year that were in our sample.
Our sample size was dictated by the time and resources our
centre possessed to perform the data extraction. The decision to
utilize a stratified random sampling with an equal number of trials
represented from each year was to obtain equal representation
from each time period so that changes over the years could be
evaluated. While this sampling allocation method may decrease
the accuracy of estimates on the global level, it will increase our
estimates for specific domains—particularly the early years when
number of trials was scarce. While this gives us relatively small
sampling fractions in later years compared to earlier years, it is
important to note that sampling fraction is a very small part of the
variance of computed estimates.
Data extraction
Data were extracted using a structured electronic form and
covered the following categories: publication characteristics (e.g.,
year of publication, journal, country of corresponding author); trial
characteristics (e.g. nature of intervention, placebo-controlled,
diagnostic category); and overall conclusions (did the study report
statistical significance for at least one outcome (yes/no), if yes,
what did it favour, overall authors’ conclusions); and methodo-
logical quality assessment.
Five staff members carried out the data extraction. Two of these
did the majority (72.4% of the studies). Staff was able to extract
data from studies in French, German, Spanish, Portuguese, Polish,
Italian and Chinese. Studies in Japanese, Dutch, Swedish and
Slovenian were extracted by volunteers under the guidance of
staff. We did not exclude any studies based on language.
Studies for which the staff member doing the data extraction
had any questions were double-checked by the centre’s scientific
director, and questions were resolved by consensus. A random
sample of 10% of the studies were pulled and double-checked by a
staff member who had not done any of the data extraction.
Differences were resolved by consensus.
Assessment of Methodological Quality
All studies were scored for methodological quality using the
Jadad scale[20], with additional questions to describe allocation
concealment, blinding, and whether an intention-to-treat analysis
was described.
Controlled Trials in Children
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To analyse trends over time, we divided our fifty-eight-year
sample into nine six-year time periods and one five-year period
(2002–2006). This division created a sufficient sample to perform
the statistical analysis. For the six-year time periods, a sample of 60
studies would give us estimates to within plus or minus 13% of
proportions (regardless of the sampling proportion).
Statistical Analysis
Weighted Horvitz-Thompson estimators were used in all compu-
tations to account for the stratified sampling design. Descriptive
statistics were presented as either means with 95% confidence
intervals for continuous variables (e.g. Jadad score) or as percentages
with 95% confidence intervals for dichotomous and categorical data.
Weighted regression analysis, both linear and logistic was performed
using the same Horvitz-Thompson weights. Trends over time were
computed on the base years, not using the summary time periods
described above. All computations were performed using SAS 9.1.
Supporting Information
Table S1 Percentage of trials from each year in sample.
Found at: doi:10.1371/journal.pone.0013106.s001 (0.01 MB
DOCX)
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